SERA · Sera Prognostics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.0K | - | $29.0K | $24.0K | $38.0K | - | $29.0K | $24.0K | $0 | - |
| Cost of Revenue | $42.0K | - | $41.0K | $20.0K | $17.0K | - | - | - | - | - |
| Gross Profit | ($28.0K) | - | ($12.0K) | $4.0K | $21.0K | - | - | - | - | - |
| R&D | $3.03M | - | $3.28M | $3.34M | $3.33M | - | $3.50M | $4.41M | $3.68M | - |
| SG&A | $4.29M | - | $4.08M | $4.14M | $4.44M | - | $4.20M | $3.75M | $4.17M | - |
| Total Operating Expenses | $9.37M | - | $9.00M | $9.34M | $9.29M | - | $8.89M | $9.28M | $9.10M | - |
| D&A | $193.0K | - | $214.0K | $208.0K | $216.0K | - | $200.0K | $200.0K | $213.0K | - |
| Operating Income | ($9.36M) | - | ($8.98M) | ($9.32M) | ($9.25M) | - | ($8.86M) | ($9.25M) | ($9.10M) | - |
| Interest Expense | $2.0K | - | $2.0K | $2.0K | $4.0K | - | $5.0K | $8.0K | $9.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($8.40M) | - | ($7.81M) | ($8.05M) | ($8.19M) | - | ($7.92M) | ($8.30M) | ($8.10M) | - |
| EPS - Basic | ($0.17) | - | ($0.16) | ($0.16) | ($0.20) | - | ($0.24) | ($0.25) | ($0.25) | - |
| EPS - Diluted | ($0.17) | - | ($0.16) | ($0.16) | ($0.20) | - | ($0.24) | ($0.25) | ($0.25) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.17M | $3.94M | $4.08M | $5.02M | $5.23M | $4.04M | $2.68M | $4.66M | $4.24M | $3.88M |
| Accounts Receivable | $11.0K | $12.0K | $14.0K | $17.0K | $25.0K | $34.0K | $79.0K | $101.0K | $117.0K | $160.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $767.0K | $862.0K | $1.04M | $1.06M | $1.21M | $1.97M | $1.38M | $952.0K | $1.03M | $1.05M |
| Current Assets | $49.73M | $40.77M | $44.49M | $40.87M | $47.28M | $47.60M | $51.11M | $51.54M | $53.85M | $61.34M |
| Total Assets | $93.54M | $101.93M | $108.13M | $111.83M | $118.18M | $72.58M | $79.00M | $84.86M | $89.89M | $95.44M |
| Current Liabilities | $23.42M | $24.19M | $23.50M | $23.60M | $23.40M | $24.77M | $24.18M | $24.76M | $24.57M | $24.44M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $25.92M | $26.52M | $25.94M | $23.60M | $23.40M | $24.77M | $24.35M | $25.11M | $25.14M | $25.28M |
| Stockholders' Equity | $67.62M | $75.41M | $82.18M | $88.23M | $94.78M | $47.80M | $54.65M | $59.75M | $64.75M | $70.16M |
| Retained Earnings | ($320.12M) | ($311.72M) | ($303.84M) | ($296.03M) | ($287.98M) | ($279.79M) | ($271.21M) | ($263.30M) | ($254.99M) | ($246.90M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($8.77M) | - | - | - | ($7.55M) | - | - | - | $4.99M | - |
| Investing Cash Flow | $8.98M | - | - | - | ($44.80M) | - | - | - | ($5.69M) | - |
| Financing Cash Flow | $20.0K | - | - | - | $53.54M | - | - | - | $1.05M | - |
| CapEx | $8.0K | - | - | - | $3.0K | - | - | - | $15.0K | - |
| Free Cash Flow | ($8.78M) | - | - | - | ($7.56M) | - | - | - | $4.98M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | -200.0% | - | -41.4% | 16.7% | 55.3% | - | - | - | - | - |
| Operating margin | -66857.1% | - | -30965.5% | -38833.3% | -24342.1% | - | -30558.6% | -38554.2% | - | - |
| EBITDA margin | -65478.6% | - | -30227.6% | -37966.7% | -23773.7% | - | -29869.0% | -37720.8% | - | - |
| Net margin | -59992.9% | - | -26944.8% | -33525.0% | -21544.7% | - | -27306.9% | -34595.8% | - | - |
| Free cash flow margin | -62728.6% | - | - | - | -19884.2% | - | - | - | - | - |
| FCF / Net income | 1.05 | - | - | - | 0.92 | - | - | - | -0.61 | - |
| R&D / Revenue | 21642.9% | - | 11324.1% | 13904.2% | 8773.7% | - | 12075.9% | 18358.3% | - | - |
| SG&A / Revenue | 30642.9% | - | 14065.5% | 17241.7% | 11694.7% | - | 14465.5% | 15633.3% | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -9.0% | - | -7.2% | -7.2% | -6.9% | - | -10.0% | -9.8% | -9.0% | - |
| Return on equity | -12.4% | - | -9.5% | -9.1% | -8.6% | - | -14.5% | -13.9% | -12.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.12 | 1.69 | 1.89 | 1.73 | 2.02 | 1.92 | 2.11 | 2.08 | 2.19 | 2.51 |
| Quick ratio | 2.12 | 1.69 | 1.89 | 1.73 | 2.02 | 1.92 | 2.11 | 2.08 | 2.19 | 2.51 |
| Cash ratio | 0.18 | 0.16 | 0.17 | 0.21 | 0.22 | 0.16 | 0.11 | 0.19 | 0.17 | 0.16 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -4680.0x | - | -4490.0x | -4660.0x | -2312.5x | - | -1772.4x | -1156.6x | -1010.8x | - |
| Equity multiplier | 1.38 | 1.35 | 1.32 | 1.27 | 1.25 | 1.52 | 1.45 | 1.42 | 1.39 | 1.36 |
| Liabilities / Assets | 0.28 | 0.26 | 0.24 | 0.21 | 0.20 | 0.34 | 0.31 | 0.30 | 0.28 | 0.26 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 287d | - | 176d | 259d | 240d | - | 994d | 1536d | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 6666d | - | 9232d | 19400d | 25915d | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.5x | - | 1.8x | 1.5x | 1.6x | - | 4.8x | 3.3x | 4.5x | - |
| P / S | 7287.5x | - | 5225.8x | 5663.1x | 4064.3x | - | 9016.5x | 8123.4x | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -63.2% | - | 0.0% | 0.0% | - | - | -31.0% | -80.5% | -100.0% | - |
| Revenue CAGR (3y) | -48.1% | - | -30.7% | -32.5% | 0.0% | - | 79.7% | 6.3% | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -1.2% | - | -1.3% | -0.7% | -1.7% | - | -8.3% | 19.3% | 19.7% | - |
| Net income growth (YoY) | -2.6% | - | 1.3% | 3.1% | -1.1% | - | -9.8% | 21.2% | 23.4% | - |
| EPS growth (YoY) | 15.0% | - | 33.3% | 36.0% | 20.0% | - | -4.3% | 26.5% | 26.5% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -16.2% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -28.7% | 57.7% | 50.4% | 47.7% | 46.4% | -31.9% | -27.5% | -26.4% | -28.2% | -29.1% |
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing SERA PROGNOSTICS against the 5 most active filers in the same SIC group.